ResMed Stock Is S&P 500’s Worst Performer. GLP-1 Drugs Are a Risk.
Wolfe Research downgraded shares of the maker of sleep-apnea airway machines to Underperform from Peer Perform.
ResMed: Growing Returns With Continuous Acquisitions Led To A Margin Of Safety
ResMed achieved double-digit revenue growth through acquisitions and operating efficiencies, with improving capital ...
bovnews5h
Resmed Inc (RMD) Stock Settles at $238.03: What’s Contributing to This Price Point?
Wolfe Research has recently reduced Resmed Inc (RMD) stock to Underperform rating, as announced on September 18, 2024, according to Finviz. Earlier, on September 4, 2024, Needham had reduced the stock ...
Top Stock Movers Now: US Steel, VF Corp., ResMed, and More
Major U.S. indexes were little changed at midday Wednesday, ahead of the Federal Reserve's decision on interest rates.
Why ResMed's Rally Is Just Getting Started
ResMed's AirSense 11 platform and myAir app enhance patient engagement and efficiency. Check out why I remain bullish on RMD ...
ResMed Faces Market Disruption and Limited Growth: A Sell Rating Analysis
Wolfe Research analyst Michael Polark downgraded the rating on Resmed (RMD – Research Report) to a Sell yesterday, setting a price target ...
We Think ResMed (NYSE:RMD) Might Have The DNA Of A Multi-Bagger
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to ...
S&P 500 Gains and Losses Today: ResMed Drops as Weight-Loss Drugs Threaten Demand
Key Takeaways The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, as the Federal Reserve announced its first interest-rate ...
Resmed (RMD) Receives a Hold from Needham
In a report released today, Michael Matson from Needham maintained a Hold rating on Resmed (RMD – Research Report). The company’s ...